25 February 2014 - Deborah Wilkes
Archived
The European Union's Pharmacovigilance Risk Assessment Committee (PRAC) has asked Takeda to provide additional data on the proton-pump inhibitor lansoprazole.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.